Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.56 |
| ▸ | LMNA | P02545 | 4/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.51 |
| ▸ | HTT | P42858 | 3/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | RORC | P51449 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12709974 | 0.87 | ALDH1A1 (0.48) | MAPTLMNAPOLBMEN1KMT2A | |
| SCHEMBL10619444 | 0.85 | ALDH1A1 (0.51) | MAPTLMNAPOLBMEN1KMT2A | |
| SCHEMBL7090078 | 0.84 | GSK3B (0.56) | MAPTLMNAPOLBMEN1KMT2A | |
| SCHEMBL29571878 | 0.84 | GSK3B (0.56) | MAPTLMNAPOLBMEN1KMT2A | |
| SCHEMBL6524346 | 0.83 | ALDH1A1 (0.49) | MAPTLMNAPOLBMEN1KMT2A | |
| SCHEMBL27400561 | 0.82 | GPR35 (0.51) | MAPTLMNAPOLBMEN1KMT2A | |
| SCHEMBL9044256 | 0.82 | TDP1 (0.54) | MAPTKMT2AALDH1A1HTTGAA | |
| SCHEMBL6554327 | 0.82 | ALDH1A1 (0.55) | MAPTLMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL29365364 | 0.82 | L3MBTL1 (0.62) | MAPTMEN1KMT2AMAPK1ALDH1A1 | |
| SCHEMBL6565927 | 0.82 | L3MBTL1 (0.62) | MAPTMEN1KMT2AMAPK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180057465-A1 | Inhibitors of Necroptosis | CATALYST THERAPEUTICS PTY LTD (AU) | 2018-03-01 | — | — | US | disclosed |
| US-20140323469-A1 | 1,4 OXAZEPINES AS BACE1 AND/OR BACE2 INHIBITORS | SIENA BIOTECH S.P.A. (IT) | 2014-10-30 | — | — | US | disclosed |
| US-20140323469-A1 | 1,4 OXAZEPINES AS BACE1 AND/OR BACE2 INHIBITORS | SIENA BIOTECH S.P.A. (IT) | 2014-10-30 | — | — | US | disclosed |
| EP-2509966-B1 | AMINO OXAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2014-10-22 | — | — | EP | disclosed |
| US-8815841-B2 | 1,4-Oxazepines as BACE1 and/or BACE2 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2014-08-26 | — | — | US | disclosed |
| US-8815841-B2 | 1,4-Oxazepines as BACE1 and/or BACE2 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2014-08-26 | — | — | US | disclosed |
| US-20140221360-A1 | USE OF AMINODIHYDROTHIAZINES FOR THE TREATMENT OR PREVENTION OF DIABETES | HOFFMANN-LA ROCHE INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140221360-A1 | USE OF AMINODIHYDROTHIAZINES FOR THE TREATMENT OR PREVENTION OF DIABETES | HOFFMANN-LA ROCHE INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140221360-A1 | USE OF AMINODIHYDROTHIAZINES FOR THE TREATMENT OR PREVENTION OF DIABETES | HOFFMANN-LA ROCHE INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-8748418-B2 | 1,4-oxazepines as BACE1 and/or BACE2 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2014-06-10 | — | — | US | disclosed |
| US-20110065695-A1 | USE OF AMINODIHYDROTHIAZINES FOR THE TREATMENT OR PREVENTION OF DIABETES | HOFFMANN-LA ROCHE, INC. | 2011-03-17 | — | — | US | disclosed |
| US-20110065695-A1 | USE OF AMINODIHYDROTHIAZINES FOR THE TREATMENT OR PREVENTION OF DIABETES | HOFFMANN-LA ROCHE, INC. | 2011-03-17 | — | — | US | disclosed |
| US-20110065695-A1 | USE OF AMINODIHYDROTHIAZINES FOR THE TREATMENT OR PREVENTION OF DIABETES | HOFFMANN-LA ROCHE, INC. | 2011-03-17 | — | — | US | disclosed |
| WO-2011029803-A1 | 2 -AMINODIHYDRO [1, 3] THIAZINES AS BACE 2 INHIBITORS FOR THE TREATMENT OF DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-17 | — | — | WO | disclosed |
| US-20100137324-A1 | RHO-KINASE INHIBITORS | NAGARATHNAM DHANAPHALAN | 2010-06-03 | — | — | US | disclosed |
| US-20100137324-A1 | RHO-KINASE INHIBITORS | NAGARATHNAM DHANAPHALAN | 2010-06-03 | — | — | US | disclosed |
| US-20100137324-A1 | RHO-KINASE INHIBITORS | NAGARATHNAM DHANAPHALAN | 2010-06-03 | — | — | US | disclosed |
| US-20060142313-A1 | Rho-kinase inhibitors | BAYER HEALTHCARE LLC | 2006-06-29 | — | — | US | disclosed |
| EP-1370553-B1 | RHO-KINASE INHIBITORS | BAYER AG (US) | 2006-05-10 | — | — | EP | disclosed |
| US-20030125344-A1 | Preferrably (indazol-5-yl)-4-quinazolinamine derivatives; antitumor agents, treating erectile dysfunction, and coronary heart disease | BAYER CORPORATION | 2003-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142313-A1 | Rho-kinase inhibitors | CIT, ROCK1, ROCK2 | MAPT 2039/4885LMNA 3659/4885POLB 2891/4885 |
| US-20140221360-A1 | USE OF AMINODIHYDROTHIAZINES FOR THE TREATMENT OR PREVENTION OF DIABETES | SLC5A2, SLC5A1, GLP1R | MAPT 3406/4885LMNA 4036/4885POLB 4630/4885 |
| US-20140323469-A1 | 1,4 OXAZEPINES AS BACE1 AND/OR BACE2 INHIBITORS | BACE1, BACE2, PSEN2 | MAPT 49/4885LMNA 3909/4885POLB 2519/4885 |
| US-20110065695-A1 | USE OF AMINODIHYDROTHIAZINES FOR THE TREATMENT OR PREVENTION OF DIABETES | SLC5A2, SLC5A1, GLP1R | MAPT 3406/4885LMNA 4036/4885POLB 4630/4885 |
| US-20030125344-A1 | Preferrably (indazol-5-yl)-4-quinazolinamine derivatives; antitumor agents, treating erectile dysfunction, and coronary heart disease | CIT, PDE3A, PDE2A | MAPT 2759/4885LMNA 4526/4885POLB 4018/4885 |
| US-20100137324-A1 | RHO-KINASE INHIBITORS | CIT, ROCK1, ROCK2 | MAPT 2039/4885LMNA 3659/4885POLB 2891/4885 |
| US-20180057465-A1 | Inhibitors of Necroptosis | RIPK3, RIPK1, AIFM1 | MAPT 3003/4885LMNA 1012/4885POLB 3512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.